Results 121 to 130 of about 153,838 (196)

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

Glycopolymeric nanoparticles transported by activated platelets protect ischemic myocardium by alleviating PANoptosis through targeting macrophage Dectin‐1

BMEMat, EarlyView.
NP‐SF, designed to target macrophage Dectin‐1 and activated platelets, selectively accumulated in ischemic myocardium, where it was taken up by macrophages after platelet hitchhiking. By inhibiting NLRC5‐related PANoptosis, NP‐SF significantly attenuated pathological damage, and effectively preserved cardiac function in a murine ischemia–reperfusion ...
Guanye Yu, Na Yang, Yan Zhang, Lingxin Peng, Yi Li, Yue Chao, Qinfang Miao, Haikun Qi, Jianhui Zhuang, Weixia Jian, Bingyu Li, Wenhui Peng, Jinghua Chen, Shiyu Gong   +13 more
wiley   +1 more source

Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a multicenter case-control study.

, 2013
Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the ...
SALVIA, Roberto, Intraductal Papillary Mucinous Neoplasm Study Group, Delle Fave G, Capurso G, BASSI, Claudio, Pezzilli R, Boccia S, Boggi U, Zerbi A, Fabbri C, Ventrucci M, Piciucchi M, Manta R, Carnuccio A, Arcidiacono PG, Tarantino I, FRULLONI, Luca, Leoncini E, Larghi A, Del Chiaro M, Costamagna G, Italian Association for Study of Pancreas   +21 more
core  

Localized Prostate Cancer Therapy: Tumor Microenvironment‐Activated Spermine Hydrogel With Real‐Time Autonomous Fluorescence Sensing

Chemistry – A European Journal, EarlyView.
First tumor microenvironment (TME)‐responsive spermine‐loaded hydrogel with autonomous sensing for advanced local therapy of prostate cancer (PCa) is developed. Spermine can be released from the hydrogel to kill the prostate cancer cells specifically under acidic TME.
Ho‐Fai Chau, Wing‐Sze Tam, Gengguo Deng, Yik Hoi Yeung, Christine Yim Ping Wong, Ka Lo Cheng, Zhengxiao Liu, Lijia Yao, Yi Wang, Angelo H. All, Chi‐Fai Ng, Jinming Di, Ka‐Leung Wong   +12 more
wiley   +1 more source

Population Pharmacokinetics and Exposure‐Response Analyses to Support Cofetuzumab Pelidotin (ABBV‐647) Dose Optimization in Non‐Small Cell Lung Cancer Patients

Clinical Pharmacology &Therapeutics, EarlyView.
Cofetuzumab pelidotin (Cofe‐P) is an anti‐protein tyrosine kinase 7 (PTK7) antibody‐drug conjugate (ADC) being investigated for the treatment of adults with PTK7‐expressing, recurrent non‐small cell lung cancer (NSCLC). The first‐in‐human (FIH) trial demonstrated tolerability of dosages ≤ 2.8 mg/kg once every 3 weeks (Q3W) and ≤ 3.2 mg/kg Q2W ...
Carla Biesdorf, Melanie Rinas, Benjamin Engelhardt, Rabih Saab, Cen Guo, Cristiano Ferlini, Kevin J. Freise, Rajeev M. Menon, Akshanth R. Polepally   +8 more
wiley   +1 more source

Dexmedetomidine infusions improve cardiovascular and renal function in anaesthetised, experimentally endotoxaemic horses

Equine Veterinary Journal, EarlyView.
Abstract Background Dexmedetomidine infusions are beneficial in anaesthetised endotoxaemic horses when administered concurrent to endotoxin, but post‐conditioning effects are unknown. Objectives To evaluate whether a dexmedetomidine infusion is beneficial in horses administered Escherichia coli O55:B5 lipopolysaccharides (LPS) endotoxin prior to ...
Sera Lee, Rachel C. Hector, Lynn Pezzanite, Eric Gilleland, Marlis L. Rezende   +4 more
wiley   +1 more source

Analgesic use, safety and pharmacokinetics of acetaminophen in equids: A structured scoping review

Equine Veterinary Journal, EarlyView.
Abstract Background Despite its frequent use in equine clinical practice, scientific data on the use of acetaminophen in horses remain limited. Objective To map and critically appraise the available evidence on the analgesic use, safety and pharmacokinetics of acetaminophen in horses. Study Design Structured scoping review.
Francisco Medina‐Bautista, Juan Manuel Serrano‐Rodríguez, María del Mar Granados   +2 more
wiley   +1 more source

Colorectal Cancer Screening in Hereditary and Familial High‐Risk Populations: Best Practices and Future Directions

International Journal of Cancer, EarlyView.
ABSTRACT Colorectal cancer (CRC) remains a leading cause of cancer‐related morbidity and mortality worldwide yet is largely preventable through effective screening and surveillance. While most CRC cases are sporadic, a substantial proportion occur in individuals at increased risk due to hereditary cancer syndromes or family history who require tailored
Ophir Gilad, Francesc Balaguer, Elizabeth E. Half, Kevin J. Monahan, Elena M. Stoffel, Sonia S. Kupfer   +5 more
wiley   +1 more source

Diabetes Increases Immunotherapy‐Related Toxicity but Not Efficacy in Metastatic Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study

International Journal of Cancer, EarlyView.
ABSTRACT This multicenter retrospective study evaluated the impact of type 2 diabetes mellitus (DM) on clinical outcomes and immune‐related adverse events (irAEs) in 450 patients with metastatic non‐small cell lung cancer (NSCLC) treated with second‐line nivolumab at 17 centers between 2016 and 2024. Among these patients, 118 (26.2%) had DM.
Emre Çakır, Didem Divriklioğlu, Deniz Can Güven, Gamze Serin Özel, Oğuzhan Yıldız, Gamze Emin, Merve Keskinkılıç, Yeşim Ağyol, Onur Yazdan Balçık, Nagihan Kolkıran, Hale Gülçin Yıldırım Doğan, Pervin Can Şancı, Özge Yalıcı, Teoman Şakalar, Yurdagül Danacı, Yakup Düzköprü, Canan Yıldız, Mesut Yılmaz, İlhan Hacıbekiroğlu, Bülent Erdoğan, Saadettin Kılıçkap, Gamze Gököz Doğu, Melek Karakurt Eryılmaz, Atila Yıldırım, İlhan Öztop, İbrahim Vedat Bayoğlu, Şahnura Uzuntaş, Atike Pınar Erdoğan, Emir Çelik, Devrim Çabuk, Erdoğan Selçuk Şeber, Zehra Sadak Öcal, Hacer Demir   +32 more
wiley   +1 more source